Registered South Africa · SAHPRA

ELUCIREM

GADOPICLENOL, (EQUIVALENT TO GADOPICLENOL 0,5 mmol AND TO GADOLINIUM 78,6 mg)

60/28/0588 3 INN generic

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
60/28/0588 3
Registration date
2026/09/08
Expiry date
-
Status
Registered
Active ingredient
GADOPICLENOL, (EQUIVALENT TO GADOPICLENOL 0,5 mmol AND TO GADOLINIUM 78,6 mg)
Dosage form
-
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
-
Applicant / LTR
Guerbet South Africa (Pty) Ltd
Country of origin
-

Source: South African Health Products Regulatory Authority · fetched 2026-10-21 04:02:28

Disclaimer: This information is sourced from South African Health Products Regulatory Authority (South Africa). Always consult a qualified healthcare professional before using any medication.

Molecular reference: gadopiclenol

PubChem CID 16223405

Molecular formula: C35H54GdN7O15

Mechanism of action

Gadopiclenol is a macrocyclic non-ionic complex of gadolinium and a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body. Its use in magnetic resonance imaging (MRI) allows to selectively increase contrast in tissues where gadopiclenol accumulates.

Pharmacodynamics

Variations in radiofrequency signal intensity allow the visualization of normal and pathological tissues during magnetic resonance imaging (MRI). These variations occur due to differences in proton density, differences of the spin-lattice or longitudinal relaxation times (T1), or differences in the spin-spin or transverse relaxation time (T2). Gadopiclenol shortens the T1 and T2 relaxation times and allows the visualization of targeted tissues during an MRI. The extent to which a contrast agent can affect the relaxation rate of tissue water (1/T1 or 1/T2) is termed relaxivity (r1 or r2). Gadopiclenol has a high r1 relaxivity compared to other gadolinium-based contrast agents. The use of gadopiclenol is not associated with QT interval prolongation; however, it can increase the risk for nephrogenic systemic fibrosis in patients with impaired elimination of the drugs. The use of gadopiclenol may also cause hypersensitivity reactions and acute kidney injury.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.